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Verapamil has been shown to depress the contractility
of ischemic myocardium. The present study was de-
signed to determine whether that effect is due to an
increase in ischemicinjury caused by the drug or whether
it might reftect a protective effect. A critical partial oc-
clusion was effected on the left anterior descending coro-
nary artery of 16 open chest foxhounds. A fiberoptic pH
probe was implanted in the subendocardium of the isch-
emic zone, and coronary blood ftowwas reduced by 79%
from a control value of 38 ± 4 mllmin and held constant.
Mean coronary perfusion pressure was decreased 48%
from its control value of 90 ± 6 mm Hg and remained
constant.
Eight animals were treated with intravenous vera-
pamil, beginning 20 to 30 minutes after the onset of
ischemia, in incremental doses (5, 10 and 20 ILglkg per
min) and eight were treated with placebo. The pH of the
ischemic zone increased after institution of treatment in
the verapamil group (+ 0.04 ± 0.05 pH unit) whereas
Verapamil selectively depresses the contractile function of
ischemic myocardium (I). This effect could be caused by
either of two mechanisms. Verapamil might be exacerbating
the intensity of the ischemic insult, and therefore the de-
crease in contractile function would reflect a deleterious
action of the drug. Alternatively, if verapamil directly de-
pressed the ischemic myocardium, the resulting decrease in
myocardial oxygen demand could exert salutary effects on
the degree of ischemic injury. Because the hydrogen ion
concentration in myocardium increases during ischemia, the
successful use of a recently developed flexible miniature
fiberoptic pH probe (2-4) implanted at a specific depth in
the left ventricular wall offered a uniquely straightforward
method to assess the effect of verapamil on tissue acidosis
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it decreased in the placebo group (- 0.06 ± 0.4 pH
unit) during the first dose (p < 0.05). Although the
difference in pH between the two groups was marked at
all doses (p < 0.03) compared with control partial oc-
clusion, verapamil caused no significant change in heart
rate (+ 0.1 ± 1 beat/min in the verapamil group versus
+ 0.6 ± 4.5 beats/min in the placebo group), mean
arterial pressure (- 7.5 ± 4 versus - 4.3 ± 3 mm Hg,
respectively) or cardiac output (- 0.2 ± 0.07 versus
- 0.02 ± 0.04 liters/min, respectively) comparing con-
trol with the first or the second dose of verapamil. The
third dose of verapamil caused large decreases in heart
rate (29%) and mean arterial pressure (23%) and caused
conduction block in most animals. Improvement of myo-
cardial acidosis after 20 to 30 minutes of ischemia as a
result of verapamil infusion confirms that verapamil ex-
erts a beneficial effect on ischemic myocardium in this
experimental model.
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as an index of ischemic injury. Thus, the present investi-
gation was undertaken to determine whether the acidosis of
ischemic myocardium improves or worsens during vera-
pamil treatment.
Methods
Experimental preparation. Sixteen male foxhounds
ranging from 23 to 34 kg in weight were anesthetized with
morphine sulfate (l rug/kg subcutaneously) and sodium pen-
tobarbital (30 mg/kg intravenously) and ventilated through
a cuffed endotracheal tube with room air or supplemental
oxygen as needed using a Harvard respirator. Standard
electrocardiographic limb leads were used, and hemody-
namic measurements were recorded on a Gould-Brush eight
channel recorder. A left thoracotomy was performed in the
fifth intercostal space and the heart was suspended in a
pericardial cradle. The aorta was dissected free and fitted
with a calibrated electromagnetic flow probe (Carolina Med-
ical Electronics) for determination of cardiac output by in-
tegrating aortic blood flow. The aortic flow signal was dif-
ferentiated electronically to yield peak acceleration of aortic
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flow (peak ejection rate) as an index of left ventricular
function (5). A catheter was placed in the right femoral
artery for measurement of phasic and mean aortic blood
pressures. Pressures were monitored by Statham P23Db
pressure transducers. A side hole catheter was inserted into
the left atrium and secured with a pursestring suture for
measurement of left atrial pressures.
The left anterior descending coronary artery was dis-
sected proximally. Heparin (10,000 U) was injected intra-
venously and the left anterior descending coronary artery
was cannulated with a perfusion system connecting the left
carotid artery to the left anterior descending coronary artery
proximal to the first diagonal branch. The perfusion system
consisted of Tygon tubing (6 rom internal diameter) equipped
with the following: a screw clamp for subsequent partial
coronary occlusion, a port between the constrictor and the
cannulating site for coronary perfusion pressure measure-
ments and a Y connection. The latter incorporated a blood-
calibrated electromagnetic flow probe (Carolina Medical
Electronics) to permit uninterrupted perfusion of the can-
nula-dependent coronary artery bed during balancing the
flowmeter at zero mechanical flow (Fig. 1). The left anterior
descending coronary artery was ligated proximally and its
distal portion was quickly cannulated with a 12 gauge blunt
needle and perfused with arterial blood through the perfusion
circuit. Heparin (6,000 U) was given intravenously at 30
minute intervals to insure cannula patency.
Determination of pH. Intramyocardial pH was mea-
sured by a miniature fiberoptic probe system which has been
previously described (2-4). In vivo validation was per-
formed in separate experiments (6). Briefly, the probe con-
sists of two optical fibers (0.075 mm in diameter) and a
0.12 mm diameter semipermeable membrane containing a
pH-sensitive dye housed in a modified 25 gauge (0.5 mm
outer diameter) stainless steel needle to facilitate implan-
tation. The two internally reflecting optical fibers are of
sufficient length that the illumination and photodetection
support module and computer system can be offset from the
experimental field.
The pH measurement system was calibrated at 37°C with
buffers of pH 6.840 and pH 7.384. In 13 animals, a single
fiberoptic probe was implanted in the subendocardium (depth
5 to 8 mm) of the potentially ischemic zone and secured by
sutures. In the last three experiments, multiple fiberoptic
probes were available for implantation. Four miniature fi-
beroptic pH probes were implanted and secured in both the
normal zone and potentially ischemic zone at depths below
the epicardial surface of 3 to 4 mm (subepicardium) and
5.5 to 8 mm (subendocardium). The two probes in each
zone were implanted within 5 to 10 mm of each other and
position was confirmed postmortem. A fifth fiberoptic probe
was implanted within the left ventricular cavity for contin-
uous on-line determination of arterial blood pH (Fig. I).
The readings of arterial blood pH measurements obtained
SCREW
CLAMP
Figure 1. Schematic illustration of the experimental preparation
depictingthe locationof intramyocardial pH probeswhen multiple
probes were available. In the majority of experiments, a single
probe was implanted in the center of the ischemiczone (IZ) in the
subendocardial (ENDO) region, as described in the text. AoF =
aortic blood flowmeter; AoP = aortic pressure;CBF = coronary
bloodflowmeter; CO = cardiacoutput;CPP = coronaryperfusion
pressure; EPI = subepicardium; LAA = left atrial appendage;
LAP = left atrial pressure; NZ = normally perfused myocardial
zone; PER = peak ejection rate.
by the fiberoptic probe were confirmed by arterial blood gas
determinations using a glass electrode (Instrumentation Lab-
oratories). The temperature of the pericardial fluid was
maintained in the physiologic range and monitored by means
of two temperature probes placed in the rectum and peri-
cardial sac.
Experimental protocol. After control measurements, a
critical coronary artery stenosis was effected by means of
an adjustable screw clamp on the carotid-left anterior de-
scending perfusion system. This was done by holding the
mean coronary perfusion pressure at 50 mm Hg and the
coronary blood flow at approximately 20% of control, such
that the reactive hyperemic response to temporary occlusion
was abolished (7). The temporary total occlusion of 15
seconds' duration was effected by means of a surgical clamp
on the perfusion tubing. With total occlusion, coronary blood
flow and coronary perfusion pressure both decreased to zero.
With release of the total occlusion, the coronary blood flow
returned to its control partial occlusion level. Similarly, the
mean diastolic perfusion pressure returned to its control level
(31 ± 13 mm Hg). Data obtained during partial occlusion
included measurements of pressures and blood flows and
continuous values of pH.
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Verapamil (n = 8) or normal saline placebo (n = 8)
was administered in a randomized fashion to different dogs
as an intravenous infusion in three incremental doses (5, 10
and 20 JLg/kg per min) using a Harvard infusion pump after
an initial bolus of 30 JLg/kg administered over 2 minutes.
Similar intravenous infusion rates have been employed clin-
ically in our institution in catheterization laboratory studies
designed to demonstrate a hemodynamic effect of the drug
(8). Infusion was begun only after the lower pH was stable
for at least 3 to 5 minutes. Hemodynamic measurements
were taken at 5 minute intervals. Each dose of drug or
placebo was administered during a 20 to 30 minute period,
and the infusion was continued until the next dose was
initiated. Although the length of the experiment was mildly
variable depending on the total time of data acquisition, the
comparison of the placebo group followed up for similar
lengths of time provides a control for any changes of the
experimental preparation over time. Serum verapamillevels
were determined by the method of Jaoni et al. (9).
After completion ofdata acquisition on the third dose of
verapamil or placebo. the animals were killed by injection
of an overdose of pentobarbital. After each experiment,
reliability of fiberoptic pH measurement was confirmed by
accurate reading of the standardization buffers.
To confirm the location of the pH probes in the ischemic
zone supplied by the left anterior descending coronary ar-
tery, we identified ischemic myocardium by injection of
Evans blue dye into the perfusion cannula. We confirmed
that the probe or probes were located at least 15 mm inside
the boundary between blue-stained ischemic tissue and un-
stained normal tissue. This procedure minimizes cqntarni-
nation of ischemic myocardium by overlapping normal zone
tissue (10,11) because this overlap occurs almost exclu-
sively within the first 5 mm inside the border between blue
and unstained tissue (II).
Table 1. Summary of Results*t
Statistics. We calculated mean :'::: standard error for group
data and tested the significance of differences by the Stu-
dent's t test for paired data or for independent samples and
analysis of variance and covariance as appropriate (12).
Differences were considered significant when p < 0.05.
Results
Baseline pH and hemodynamic data for both treatment
and control groups show no significant differences between
those animals given veraparnil and those given placebo either
in the preocclusion state or after partial occlusion (Table
I). Comparison of the differences between the preocclusion
versus partial occlusion within the same group is shown by
the p value.
Myocardial pH. The pH data from a representative ex-
periment are shown in Figure 2. The initial small decrease
in pH recorded over the first 30 minutes from pH 7.50 to
7.44 is due to respirator adjustments to achieve a normal
arterial blood pH. The pH of the ischemic zone decreased
from 7.43 to 7.24 by 10 minutes after partial coronary artery
occlusion, whereas the pH of arterial blood and of the nor-
mally perfused myocardium were unaffected. After 50 min-
utes of partial coronary artery occlusion, the pH in the
ischemic zone was 6.90. The pH was stable in the range of
6.92 to 6.90 for 5 minutes before the initiation of verapamil
infusion. After continued infusion of verapamil in incre-
mental doses, pH increased toward the level of the normal
zone pH. The pH of arterial blood and of the normal zone
did not change under the influence of verapamil. With ven-
tricular fibrillation, all probes recorded precipitous decreases
in pH, confirming the continued ability of the probes to
respond to changing hydrogen ion concentrations.
Ischemic zone pH increased in the verapamil-treated dogs
compared with the control group (Fig. 3). The effect was
Group pH HR MAP CBF CPP CPPd PER LAP CO PVR
A. Treatment (VRP)
Preocclusion 7.46 ± 0.02 135 ± 7 86 ± 5 42 ± 6 85 ± 6 71 ± 4 4.8 ± 0.4 5 ± I 1.2 ± 0.1 75 ± 12
(n) (8) (8) (8) (8) (4) (8) (6) (7) (5) (5)
Partial occlusion 7. \I ± 0.05 127 ± 9 77 ± 5 9 ± I 46 ± 3 31 ± 3 4.4 ± 0.08 6 ± I 1.2 ± 0.1 72 ± 9
(n) (8) (8) (8) (7) (7) (8) (4) (7) (5) (5)
P Value <0.001 NS NS <0.01 <0.035 <0.001 NS NS NS NS
B. Control (placebo)
Preocclusion 7.42 ± 0.02 150 ± 9 99 ± 6 34 ± 4 95 ± 8 78 ± 6 3.9 ± 0.3 4 ± 2 1.1 ± 0.1 94 ± \0
(n) (6) (8) (8) (8) (5) (8) (5) (8) (5) (4)
Partial occlusion 7.18 ± 0.05 151 ± 8 92 ± 6 7 :t I 38 :t 4 29 :t 5 3.5 ± 0.1 4 ± 2 0.9 :t 0.1 \03 ± 7
(n) (8) (8) (8) (7) (5) (8) (4) (8) (5) (5)
P Value <0.005 NS NS <0.001 <0.005 <0.001 NS NS NS NS
*Values are expressed as mean :t SEM. tThere are no statistically significant differences (by Student's unpaired I test) between Groups A and B
preocclusion~between Groups A and B after partial coronary artery occlusion. CBF = mean coronary blood flow (rnl/rnin); CO = cardiac output
(liters/min); CPP = mean coronary perfusion pressure (mm Hg); CPPd = diastolic coronary perfusion pressure (mm Hg); HR = heart rate (beats/min);
LAP = mean left atrial pressure (mm Hg); MAP = mean arterial pressure (mm Hg); PER = peak ejection rate (liters/min); PVR = calculated peripheral
vascular resistance (mm Hglliter per min); VRP = verapamil.
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Figure 2. Representative experiment demonstrat-
ing a beneficial effect of verapamil (VRP) on pH
of ischemic myocardium. The pH is graphed against
time in minutes. An intracavitary fiberoptic probe
(solid squares) reflects arterial blood (AB) pH. Data
from the fiberoptic probe in the normally perfused
zone (NZ) are denoted by the solid circles and those
from the probe in the ischemic zone (IZ) are denoted
by the solid triangles. The pH of the probe in the
ischemic zone can be seen to increase with vera-
pamil treatment. The responsiveness of all probes
to changing hydrogen ion concentration can be seen
with the continuous decrease in registered pH values
after spontaneous ventricular fibrillation (VF) (dot-
ted vertical line). See text for further discussion.
particularly apparent with the first (5 JLg/kg per min) and
the second (10 JLg/kg per min) doses, although all three
doses resulted in a higher pH compared with placebo-treated
dogs (p < 0.03 by analysis of covariance). While the third
dose of verapamil reduced aortic pressure, it actually caused
a decrease in pH, but this decrease was not as great as the
decrease in the placebo-treated group. Control values of
intramyocardial pH before verapamil infusion were actually
lower (Fig. 3A), suggesting more severe ischemia in the
verapamil treatment group (pH 7.11 ± 0.05) compared with
the control group (pH 7.18 ± 0.05), but the difference was
not significant (Table 1). Individual data points are presented
in Figure 4, which shows a group trend of improved pH
(range 0.16 to 0.31 pH units, mean 0.22 ± 0.04) of isch-
emic myocardium during verapamil infusion.
Determinants of myocardial oxygen supply and de-
mand. Coronary blood flow (Fig. SA) was reduced to 21%
of control (p < 0.01) by partial coronary occlusion in the
treatment group and to 20% of control (p < 0.001) in the
control group (Table 1). The difference between the two
postpartial occlusion measurements is not significant. Coro-
nary blood flow was held constant during three doses of
verapamil and measured 6 ± I, 9 ± I and 9 ± I mllmin
with each dose of verapamil compared with 9 ± 2, 7 ± 2
and 8 ± 4 mllmin with each dose of placebo (Fig. SA).
Analysis of covariance confirmed no difference in coronary
blood flow between the two groups. Coronary perfusion
pressure distal to the partial occlusion (Fig. 58) decreased
with partial occlusion (90 ± 5 versus 43 ± 3 mm Hg;
p < 0.03), but it did not decrease further during verapamil
infusion.
Figure 6A demonstrates a marked dose-related decrease
in heart rate in the verapamil-treated group. The third dose
of verapamil (20 JLg/kg per min) had profound negative
chronotropic and dromotropic effects. Conduction distur-
bances occurred in all dogs in the verapamil group and
p<.03 p<.03 Figure 3. Effect of verapamil on ischemic
A B zone pH. Panel A displays the pH value
for both groups of animals 20 to 30 minutes
after partial coronary occlusion (peO) and
7.3
for each of three incremental doses (0 I,
02 or 03) of verapamil (V) or placebo (P).
+.20 Note that pH during partial coronary oc-
L c1usionwas slightly lower in the group sub-7.2 +.15 sequently treated with verapamil (solid line).
:I:
'"J
0 Panel B shows the percent change of meanc. r-- u +.10 pH for both groups. The pH is shown to bez 0.« ~ significantly higher in the verapamil-treatedw 7.1~ 0 +.05a: group (solid line) at all doses by analysisu,
:I: 0 of covariance (p < 0.03). In both panelsc. ,
~
""f----i", and in the following figures, the verapamil-7.0 w -.05o treated dogs are designated by solid tri-z
«
-.10 angles and the control animals by solid:I: ,
U , circles. The number of animals in the vera-,,
pamil (V) and placebo (P) groups at each6.9 -.15
dose are included on the horizontal axis.
PCO 01 02 03 PCO 01 02 03 Bars represent mean ± 1 SEM. See text
"Vln=8) 10=8) 10=5) 10=5) .. V (0=8) V 10=8) V In=5) V (0=51 for further discussion.
• Plo=8) (0=8) 10=5) 10=5) • P (n=8) P 10=8) P In=5) P (0=51
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Figure 4. Individual pH responses are depicted graphically for
the veraparnil-treated animals (solid triangles connected by solid
line) and the placebo-treated animals (solid circles connected by
dashed line). The vertical axis depicts pH, while the horizontal
axis designates times of partial coronary artery occlusion (PCO)
and doses of drug (V) or placebo (P) (0 I, 02 and 03).
included sinus bradycardia, first and second degree atrio-
ventricular (AV) block (Mobitz type I) and complete heart
block in one dog. Only mild increases in the PR interval
were seen with the first and second doses. Analysis of co-
variance confirmed no difference in heart rate between the
verapamil-treated group and the placebo group for the first
and second doses, although the decrease was significant for
7.4
7.2
~ 7.1
7.0
6.9
6.8
........_---...
----...
pea D I D2 D3
• V(n~8) V(n~8) V(n~5) V(n~5)
• P(n~8) P(n~8) P(n~5) P(n~5)
all three doses (p < 0.04). Verapamil dosage was linearly
related to serum verapamil levels. The adequacy of the
loading dose was apparent because serum levels after the
loading dose approximated those achieved with the initial
dose of verapamil. Although verapamil caused a significant
reduction in mean arterial pressure, considering all three
doses (p < 0.02), the changes were not significant with the
first two doses of verapamil employed.
Several indexes of left ventricular function decreased
progressively with increasing doses of verapamil. When
assessed by one way analysis of variance, cardiac output
(Fig. 7B) (p < 0.04) and peak ejection rate (Fig. 7C) (p <
0.04) decreased significantly. Analysis of variance showed
no significant difference in left atrial pressure between the
control and treatment groups (Fig. 7A), but the relation
between left atrial pressure and cardiac output indicated
diminished cardiac function with verapamil (Fig. 8). This
representation of the Starling relation demonstrates that the
ventricular function curve is depressed by verapamil.
Discussion
Protective effect of verapamil in ischemia. Verapamil
is clinically effective in the treatment of ischemic heart
disease (13-16). In theory, the drug may favorably affect
both oxygen supply and demand. A previous study (I) showed
that verapamil selectively depresses the contractile function
of ischemic myocardium; that is, doses that exert no effect
on contractile function of normal zone myocardium signif-
icantly diminish contractile function of ischemic tissue. A
more recent study from our laboratory (17) demonstrated
reduced global and regional function with verapamil treat-
ment in awake animals with partial coronary occlusion. By
p = N.S. p = N.S. p = N.S.
A B C
50 100 ~ 100
Figure 5. Coronary hemodynamic 40 8J 80 ~measurements. Mean artery blood flow
(CBF, panel A), mean coronary per-
:£ '0, D>fusion pressure (CPP, panel B) and :rL~) E :r60 E 60diastolic coronary perfusion pressure E E E(CPPd , panel C) are shown for the u, c, '0al e,
U o
_.l'J
~
verapamil-treated group (solid trian- e,z z o
gles) and control animals (solid cir- ~2O « 40 z 40w
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cles). These graphs demonstrate no ~ w~
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pressures between the two groups. 10 20 20
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Figure 6. Effectof verapamil on heart rate,
mean aortic pressure and peripheral vas-
cular resistance. Percent change in heart
rate (HR, panel A), mean arterial pressure
(MAP, panel B) and peripheral vascular
resistance (PVR, panel C) from control
values in the verapamil group (solid tri-
angles) and placebo group (solid circles)
are graphed against experimental interven-
tion. PCO = partial coronary artery occlu-
sion. DI, D2 and D3 refer to the incre-
mental doses of verapamil (V) or placebo
(P). The number of data points included in
the verapamil or placebo groups at each
interventionis shown along the horizontal
axis.
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documenting that verapamil treatment improves pH of isch-
emic myocardium, our study suggests that the depression
of cardiac function is a primary drug effect that results in
amelioration of ischemia-induced acidosis, rather than a
secondary drug effect resulting from a worsening of isch-
emic injury to the myocardium. This beneficial effect to
depress cardiac function might be viewed as if the drug were
"splinting" the ischemic myocardium, thereby reducing
local myocardial oxygen demand and diminishing ischemia
in the jeopardized region.
If intramyocardial pH is considered as an indicator of
the balance between myocardial oxygen supply and demand
in the presence of myocardial ischemia, then one can assess
the mechanism by which veraparnil might improve pH. Other
experiments in this laboratory show a good correlation be-
tween intramyocardial pH and the reduction in coronary
blood flow (r = 0.80), myocardial concentration of lactate
(r = 0.88) and adenosine triphosphate (r = 0.78) (Ro and
Patterson, unpublished observations). Oxygen delivery to
the ischemic myocardium was held constant by design in
these experiments to assess effects on oxygen demand and
ischemic injury. We employed three doses of verapamil in
an attempt to separate the multiple potential effects of this
calcium channel blocking agent. Verapamil decreased heart
p = N.S. p<.02 p<.04
+40 +40 +40
+30 J +30 +30 J\11/ Figure 7. Effectof verapamilon indexes~+2O 8+20 ~+2O of left ventricular function. The percentll. 1 I change in mean left atrial pressure (LAP,~+10 ...1// ~+10 I~~.1O II panel A), cardiac output (CO, panel B)a: a: a: a: j... u,
-J'/ , Z'" and peak ejection rate (panel C) aredem-ll.W 0 ... W 0 \ QW 0 ~:5lE O<.'l , I- <.'l onstrated. Althoughthere is no significantuz u Z< ~ -10 w< change in mean left atrial pressure be-i5 -10 o ;;) i5 -10 tween the two groups at all doses, therel- I- "'I-~ -20 ~ -20 ~~ -20 is a dose-relatedreduction in cardiac out-o oa: a: a: put and peak ejection rate in the verapa-It' -30 It' -30 It' ·30
mil-treated group (p < 0.04).
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Figure 8. Effect of verapamil on left ventricular
function (Starling curve). The percent change in
cardiacoutputof verapamil-treated (solidtriangles)
andplacebo-treated (solidcircles) animals is shown
graphed againstthe meanleft atrialpressure (LAP).
The data pointsare designated for each of the three
incremental doses by an arabic numeral associated
with the letter V (for verapamil-treated) or P (for
placebo-treated). This representation of the Starling
relation indicates a depression of cardiac output at
the sameor highervalues of leftatrialpressure with
verapamil (p < 0.05 by analysis of variance).
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rate, aortic pressure, cardiac output and peak ejection rate
when all doses were considered. At the two lowest doses,
however, verapamil improved the pH of the ischemic myo-
cardium without significantly affecting the heart rate or mean
aortic pressure (Fig. 6). An improvement in pH was apparent
with the first dose of verapamil before any hemodynamic
change, suggesting that the protective effect of verapamil
is independent of the indexes of myocardial oxygen demand
or supply measured in this study. It is quite possible that
ischemic regional function had decreased because this result
was found using similar doses in an earlier study from our
laboratory (17). Another study from our laboratory (I) in-
dicated that verapamil selectively depressed contractility of
ischemic myocardium to diminish myocardial oxygen de-
mand in the ischemic region without significant effect on
global function.
Critique of methods. Our conclusion that verapamil im-
proved pH of ischemic myocardium seems justifiable by the
methods employed and results obtained. The selection of
the open chest model was dictated by technical considera-
tions relating to implantation of the flexible fiberoptic pH
probe. We employed a model of critical partial coronary
occlusion to stimulate angina pectoris resulting from mod-
erate transient ischemia. Because the stenosis was effected
to eliminate the reactive hyperemic response and reduce
coronary blood flow, the ischemic bed in this model was
presumably maximally dilated. The beneficial verapamil ef-
fect was not due to any coronary vasodilator effect because
coronary blood flow was held constant by design (Fig. SA).
An acute partial coronary occlusion does not present much
stimulus to collateral flow because the coronary pressure
distal to the obstruction does not fall far enough below
coronary pressure at the origin of the collateral vessels to
provide a high drive pressure gradient for collateral myo-
cardial blood flow (I8). In support of this interpretation, a
previous study from our laboratory (19) showed that vera-
pamil had no effect on collateral blood flow. We did not
measure an increase in peripheral coronary pressure, which
should have increased if collateral vessels had delivered
more flow (Fig. SC) (18). In addition, by holding coronary
flow constant and observing a constant coronary artery pres-
sure and left atrial pressure, it is unlikely that changes in
transmural distribution of blood flow were causing major
changes in tissue blood flow because the transmural gradient
of pressure between coronary artery and left ventricular
filling pressure was constant (20).
Possible mechanisms. We were able to demonstrate a
beneficial effect of verapamil treatment even though treat-
ment began 20 to 30 minutes after critical partial coronary
artery occlusion. This respresents an important finding in
that it indicates that verapamil can lessen ongoing ischemic
myocardial injury. Sherman et al. (21) also demonstrated a
beneficial effect of verapamil on ischemic canine myocar-
dium independent of heart rate or myocardial blood flow.
This protective effect on the ischemic zone was evidenced
by preserved postextrasystolic potentiation, an index of the
latent contractile response, in the verapamil-treated animals.
Regional systolic shortening in the ischemic zone was abol-
ished equally in control and verapamil-treated dogs, but
postextrasystolic potentiation was preserved only in vera-
pamil-treated dogs (21). The possibility that verapamil im-
proved pH by direct blockade of calcium entry into ischemic
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cells (22,23) cannot be confirmed or refuted by our exper-
iment, but this possibility is not necessary to explain the
results of our study.
Because these animal studies were performed in dogs
having no evidence of heart failure, it is possible that vera-
pamil-induced reduction of left ventricular function might
not improve pH in the setting of left ventricular failure.
Decreased left ventricular function might increase wall ten-
sion and oxygen demands in ischemic myocardium in the
failing heart and lead to an opposite effect of verapamil on
pH. Thus, it should not be assumed that verapamil improves
myocardial pH in all settings of acute myocardial ischemia.
Conclusions. Our study demonstrates a beneficial effect
of verapamil on myocardial ischemic injury in an experi-
mental model designed to represent fixed atherosclerotic
lesions where there would be no element of coronary spasm
involved. This beneficial effect was observed even though
treatment was not started until several minutes after the onset
of ischemia. The favorable effects of verapamil on pH of
ischemic myocardium were associated with no change in
coronary hemodynamic measurements distal to the partial
coronary occlusion, indicating that the favorable effects could
not be attributed to improved tissue blood flow. This im-
provement in pH was evident during the lowest dose before
systemic hemodynamic changes were apparent. These find-
ings with verapamil in an animal model of myocardial isch-
emia offer objective evidence of improved metabolism of
ischemic myocardium and may represent one of the mech-
anisms responsible for the antianginal effect of verapamil
observed in patients.
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